|
1
|
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.
|
J Exp Med
|
2008
|
3.48
|
|
2
|
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
|
Blood
|
2013
|
3.45
|
|
3
|
T cell immune reconstitution following lymphodepletion.
|
Semin Immunol
|
2007
|
2.35
|
|
4
|
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients.
|
J Exp Med
|
2005
|
2.30
|
|
5
|
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
|
Clin Cancer Res
|
2013
|
1.60
|
|
6
|
Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.
|
Clin Cancer Res
|
2010
|
1.44
|
|
7
|
Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function.
|
Blood
|
2004
|
1.42
|
|
8
|
Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa.
|
Blood
|
2009
|
1.20
|
|
9
|
Dysregulation of IL-15-mediated T-cell homeostasis in TGF-beta dominant-negative receptor transgenic mice.
|
Blood
|
2006
|
1.19
|
|
10
|
Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels.
|
Biol Blood Marrow Transplant
|
2008
|
1.11
|
|
11
|
Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation.
|
Biol Blood Marrow Transplant
|
2010
|
1.05
|
|
12
|
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
|
Blood
|
2013
|
0.99
|
|
13
|
Quantitative analysis of T cell receptor diversity in clinical samples of human peripheral blood.
|
J Immunol Methods
|
2011
|
0.92
|
|
14
|
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
|
Blood
|
2012
|
0.90
|
|
15
|
Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo.
|
Stem Cells
|
2015
|
0.83
|
|
16
|
The thymus and the immune system: layered levels of control.
|
J Thorac Oncol
|
2010
|
0.81
|
|
17
|
Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.
|
Clin Cancer Res
|
2011
|
0.79
|
|
18
|
Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation.
|
Blood
|
2011
|
0.79
|
|
19
|
Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
0.77
|
|
20
|
Erratum to "Salivary Gland Involvement in Chronic Graft-versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation" [Biol Blood Marrow Transplant 16:1362-1369].
|
Biol Blood Marrow Transplant
|
2015
|
0.75
|